This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Huggins, J.
Right arrow Articles by Hruby, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huggins, J.
Right arrow Articles by Hruby, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2009, p. 2620-2625, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.00021-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246{triangledown}

John Huggins,1 Arthur Goff,1 Lisa Hensley,1 Eric Mucker,1 Josh Shamblin,1 Carly Wlazlowski,1 Wendy Johnson,1 Jennifer Chapman,1 Tom Larsen,1 Nancy Twenhafel,1 Kevin Karem,2 Inger K. Damon,2 Chelsea M. Byrd,3 Tove' C. Bolken,3 Robert Jordan,3 and Dennis Hruby3*

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland,1 Centers for Disease Control and Prevention, Atlanta, Georgia,2 SIGA Technologies, Corvallis, Oregon3

Received 6 January 2009/ Returned for modification 18 February 2009/ Accepted 25 March 2009

ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival.

* Corresponding author. Mailing address: SIGA Technologies, Inc., 4575 SW Research Way, Corvallis, OR 97333. Phone: (541) 753-2000. Fax: (541) 753-9999. E-mail: dhruby{at}siga.com

{triangledown} Published ahead of print on 6 April 2009.

Antimicrobial Agents and Chemotherapy, June 2009, p. 2620-2625, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.00021-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Berhanu, A., King, D. S., Mosier, S., Jordan, R., Jones, K. F., Hruby, D. E., Grosenbach, D. W. (2009). ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation. Antimicrob. Agents Chemother. 53: 4999-5009 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»